MB-CAR-T19-22 / Miltenyi Biotec - LARVOL DELTA

Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL (clinicaltrials.gov) - P1/2 | N=50 | Active, not recruiting | Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Mar 2027 | Trial primary completion date: Dec 2022 ➔ Mar 2022

Enrollment closed • Trial completion date • Trial primary completion date • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics • CD19 • CD22